The RECAP2 Study: Midazolam and Psilocybin

Recruiting now · Phase 1 · Has a placebo group

Conditions studied: Psilocybin

In brief

The goal of this clinical trial is to learn about the role that inducing neuroplasticity (the brain's ability to adapt and change) plays in the behavioral effects of psilocybin in people who have experienced a mild decline in emotional wellbeing. Researchers will compare different doses of psilocybin combined with midazolam or placebo to see what dose induces increased wellbeing. Participants will: * Receive one of four possible combinations of medications * Undergo an MRI * Complete questionnaires * Undergo transcranial magnetic stimulation (TMS) and EEG

Key facts

Study ID
NCT06692192
Run by
University of Wisconsin, Madison
People needed
60
Starts
2025-08-07
Expected to finish
2027-12-01
Last updated by the study team
2026-04-03

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.